neaumycin B: isolated from the soil actinomycete Streptomyces sp. NEAU-x211; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Neaumycin B is a complex polycyclic macrolide possessing 19 asymmetric centers. It is a femtomolar inhibitor of U87 human glioblastoma.
| Excerpt | Reference |
|---|---|
| "Neaumycin B is a femtomolar inhibitor of U87 human glioblastoma. " | ( Ruthenium-Catalyzed Butadiene-Mediated Crotylation and Oxazaborolidine-Catalyzed Vinylogous Mukaiyama Aldol Reaction for The Synthesis of C1-C19 and C23-C35 of Neaumycin B. Krische, MJ; Liang, X; Maejima, S; Schempp, T; Yoo, M, 2022) |
| "Neaumycin B is a complex polycyclic macrolide possessing 19 asymmetric centers, usually requiring selective degradation, crystallization, derivatization, X-ray diffraction analysis, synthesis, or other time-consuming approaches to assign the complete stereostructure." | ( Integration of Genomic Data with NMR Analysis Enables Assignment of the Full Stereostructure of Neaumycin B, a Potent Inhibitor of Glioblastoma from a Marine-Derived Micromonospora. Fenical, W; Jang, KH; Jensen, PR; Kim, MC; Machado, H; Trzoss, L, 2018) |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||